Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

Pediatric Nephrology

Volumn 22, Issue 6, 2007, Pages 893-898

  Smith, Graham C ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Child; Nephrotic syndrome; Rituximab

Indexed keywords

ALBUMIN; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ARTICLE; BODY HEIGHT; CASE REPORT; CHILD; CHILD GROWTH; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; GLOMERULAR MESANGIUM; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; TREATMENT OUTCOME;

EID: 34247326833     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0427-5     Document Type: Article

References (54)

1. Sharma M, Sharma R, McCarthy ET, Savin VJ (1999) 'The FSGS factor': enrichment and in vivo effect of activity from focal segmental glomerulosclerosis factor. J Am Soc Nephrol 10:552-561
2. Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574-581
3. Tanaka R, Yoshikawa N, Nakamura H, Ito H (1992) Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 60:35-41
4. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453-460
5. Couser W, Badger A, Cooperband S, Stilmand M, Jermanovich N, Aurora S, Doner D, Schmitt G (1977) Hodgkin's disease and lipoid nephrosis. Lancet i:912-913
6. Belghiti D, Vernant JP, Hirbec G, Gubler MC, Andre C, Sobel A (1981) Nephrotic syndrome associated with T-cell lymphoma. Cancer 47:1878-1882
7. McDonald P, Kalra PA, Coward RA (1992) Thymoma and minimal-change glomerulonephritis. Nephrol Dial Transplant 7:357-359
8. Hardwicke J, Soothill J, Squire J, Holti G (1959) Nephrotic syndrome associated with pollen hypersensitivity. Lancet i:450
9. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP (1994) Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330:7-14
10. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoabsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709-1715
11. Szeto C, Gillespie KM, Mathieson PW (2000) Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 100:217-224
12. Kimata H, Fujimoto M, Furusho K (1995) Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 25:1497-1501
13. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529-537
14. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined B- and T-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242-247
15. Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after Rituximab therapy. Pediatr Nephrol 19:794-797
16. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660-1663
17. Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961-1963
18. Gilbert RD, Rigden SPA (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698-1700
19. Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S (2006) Early recurrence nephrotic syndrome (immunoglobulin M nephropathy) after renal transplantation successfully treated with combinations of plasma exchange, immunoglobulin, and rituximab. Transplant Proc 38:2659-2660
20. Kemper MJ, Möller K, Ludwig K, Rink N, Möller-Wiefel (2006) Rituximab (RTX) in the treatment of refractory steroid sensitive nephrotic syndrome (abstract). Pediatr Nephrol 21:1528
21. Dallochio IA, Trimoreau F, Feuillard J, Guigonis V (2006) A case of steroid-dependent nephrotic syndrome treated with rituximab (abstract). Pediatr Nephrol 21:1615
22. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
23. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of Rituximab on primary non-Hodgkins lymphomas. Blood 101:949-954
24. Maloney DG, Smith B, Rose A (2002) Rituximab: Mechanism of action and resistance. Semin Oncol 29 [Suppl 2]:2-9
25. Robak T (2004) Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79-88
26. Raj A, Bertolone S, Cheerva A (2004) Successful treatment of refractory autoimmune hemolytic anemia with monthly Rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol 26:312-314
27. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-3861
28. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with Rituximab. Lancet 358:1511-1513
29. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ, LoBuglio AF (2000) A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99-103
30. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-957
31. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538-546
32. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232-239
33. Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701-1704
34. Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD (2003) Treatment of IgM antibody associated polyneuropathies using Rituximab. J Neurol Neurosurg Psychiatry 74:485-489
35. Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, Sanchez P, Illa I (2003) Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to Rituximab. Neurology 61:1814-1816
36. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611-615
37. Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17:599-605
38. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP (2002) Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426-3428
39. Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum 52:262-268
40. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with Rituximab. J Intern Med 257:540-548
41. Stahl HD, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Edwards JCW, Clase DR, Stevens RM, Shaw TM (2003) Rituximab in rheumatoid arthritis: Efficacy and safety from a randomized controlled trial. Ann Rheum Dis 62 [Suppl]:0P004
42. Shaw T, Quan J, Totoritis MC (2003) B cell therapy for rheumatoid arthritis: The Rituximab (anti-CD20) experience. Ann Rheum Dis 62 [Suppl 2]:iI55-ii59
43. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581
44. DeVita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029-2033
45. Tuscano JM (2002) Successful treatment of infliximab-refractory rheumatoid arthritis with Rituximab. Arthritis Rheum 46:3420
46. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673-2677
47. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459
48. Eisenberg R (2003) Mechanisms of autoimmunity. Immunol Res 27:203-218
49. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of Rituximab. Arthritis Rheum 50:2580-2589
50. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168-3174
51. Johnson PWM, Glennie MJ (2001) Rituximab; mechanisms and applications. Br J Cancer 85:1619-1623
52. Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517-527
53. Silverman GJ, Carson DA (2003) Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 5 [Suppl 4]:S1-S6
54. Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA (2004) B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum 50:S447